Ralinepag Delivers Landmark 55% Risk Reduction in Clinical Worsening for Pulmonary Arterial Hypertension Patients in Pivotal Phase 3 Trial
“In a groundbreaking phase 3 ADVANCE OUTCOMES study, United Therapeutics’ investigational oral prostacyclin agonist ralinepag achieved a highly significant 55%…
